IP Library › Granted Patent US 12,496,314
Granted Patent B2
US 12,496,314 · App. 17/784,392 · Granted Dec 16, 2025

Antigen-binding domain

Inventors: Shimobi Onuoha (London, GB); Mathieu Ferrari (London, GB); Marco Della Peruta (London, GB); Alexander Kinna (London, GB); Shaun Cordoba (London, GB)
Assignee: AUTOLUS LIMITED
A61K35/17A61K40/11A61K40/31A61K40/4276C07K16/3069A61K2239/13A61K2239/58C07K2317/22C07K2317/565C07K2317/569C07K2317/73C07K2317/92C07K2317/94C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,314
App. No.
17/784,392
Granted
Dec 16, 2025
Kind
B2
Abstract

The present disclosure relates to antigen-binding domains which bind the antigen prostate-specific membrane antigen (PSMA) and to chimeric antigen receptors (CARs) which comprise such antigen binding domains.

Claims (35)

1 . An antigen-binding domain which binds prostate-specific membrane antigen (PSMA) and comprises either:

(a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3; and a light chain variable region (VL) having CDRs LCDR1, LCDR2 and LCDR3:

(i) HCDR1 comprising SEQ ID NO. 1; HCDR2 comprising SEQ ID NO. 2; HCDR3 comprising SEQ ID NO. 3; LCDR1 comprising SEQ ID NO. 4; LCDR2 comprising SEQ ID NO. 5; LCDR3 comprising SEQ ID NO. 6;

(ii) HCDR1 comprising SEQ ID NO. 9; HCDR2 comprising SEQ ID NO. 10; HCDR3 comprising SEQ ID NO. 11; LCDR1 comprising SEQ ID NO. 12; LCDR2 comprising SEQ ID NO. 13; LCDR3 comprising SEQ ID NO. 14;

(iii) HCDR1 comprising SEQ ID NO. 17; HCDR2 comprising SEQ ID NO. 18; HCDR3 comprising SEQ ID NO. 19; LCDR1 comprising SEQ ID NO. 20; LCDR2 comprising SEQ ID NO. 21; LCDR3 comprising SEQ ID NO. 22;

(iv) HCDR1 comprising SEQ ID NO. 25; HCDR2 comprising SEQ ID NO. 26; HCDR3 comprising SEQ ID NO. 27; LCDR1 comprising SEQ ID NO. 28; LCDR2 comprising SEQ ID NO. 29; LCDR3 comprising SEQ ID NO. 30;

(v) HCDR1 comprising SEQ ID NO. 33; HCDR2 comprising SEQ ID NO. 34; HCDR3 comprising SEQ ID NO. 35; LCDR1 comprising SEQ ID NO. 36; LCDR2 comprising SEQ ID NO. 37; LCDR3 comprising SEQ ID NO. 38;

(vi) HCDR1 comprising SEQ ID NO. 41; HCDR2 comprising SEQ ID NO. 42; HCDR3 comprising SEQ ID NO. 43; LCDR1 comprising SEQ ID NO. 44; LCDR2 comprising SEQ ID NO. 45; LCDR3 comprising SEQ ID NO. 46; or

(vii) HCDR1 comprising SEQ ID NO. 49; HCDR2 comprising SEQ ID NO. 50; HCDR3 comprising SEQ ID NO. 51; LCDR1 comprising SEQ ID NO. 52; LCDR2 comprising SEQ ID NO. 53; LCDR3 comprising SEQ ID NO. 54; or

(b) a domain antibody variable region having complementarity determining regions (CDRs) VHHCDR1, VHHCDR2, and VHHCDR3:

(i) VHHCDR1 comprising SEQ ID NO. 33; VHHCDR2 comprising SEQ ID NO. 34; VHHCDR3 comprising SEQ ID NO. 35;

(ii) VHHCDR1 comprising SEQ ID NO. 37; VHHCDR2 comprising SEQ ID NO. 38; VHHCDR3 comprising SEQ ID NO. 39;

(iii) VHHCDR1 comprising SEQ ID NO. 41; VHHCDR2 comprising SEQ ID NO. 42; VHHCDR3 comprising SEQ ID NO. 43;

(iv) VHHCDR1 comprising SEQ ID NO. 45; VHHCDR2 comprising SEQ ID NO. 46; VHHCDR3 comprising SEQ ID NO. 47; or

(v) VHHCDR1 comprising SEQ ID NO. 49; VHHCDR2 comprising SEQ ID NO. 50; VHHCDR3 comprising SEQ ID NO. 51.

2 . An antigen-binding domain according to claim 1 , which comprises either:

(a) a heavy chain variable region (VH); and a light chain variable region (VL):

(i) VH comprising SEQ ID NO. 7 and VL comprising SEQ ID NO. 8;

(ii) VH comprising SEQ ID NO. 15 and VL comprising SEQ ID NO. 16;

(iii) VH comprising SEQ ID NO. 23 and VL comprising SEQ ID NO. 24; or

(iv) VH comprising SEQ ID NO. 31 and VL comprising SEQ ID NO. 32; or

(b) a domain antibody variable region:

(i) SEQ ID NO. 36;

(ii) SEQ ID NO. 40;

(iii) SEQ ID NO. 44;

(iv) SEQ ID NO. 48; or

(v) SEQ ID NO. 52.

3 . A chimeric antigen receptor (CAR) comprising an antigen-binding domain according to claim 1 .

4 . A nucleic acid sequence which encodes an antigen-binding domain according to claim 1 .

5 . A nucleic acid construct which comprises a nucleic acid sequence according to claim 4 and a nucleic acid sequence which encodes a suicide gene.

6 . A vector which comprises a nucleic acid sequence according to claim 5 .

7 . A cell which expresses a CAR according to claim 3 .

8 . A method for making a cell according to claim 7 , which comprises the step of introducing a nucleic acid sequence which encodes a CAR according to claim 3 into a cell ex vivo.

9 . A pharmaceutical composition which comprises a plurality of cells according to claim 7 and a pharmaceutically acceptable carrier, diluent or excipient.

10 . A method for treating cancers that overexpress prostate specific membrane antigen which comprises the step of administering a cell according to claim 7 to a subject.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: ONUOHA, SHIMOBI; FERRARI, MATHIEU; PERUTA, MARCO DELLA; KINNA, ALEX; CORDOBA, SHAUN
To: AUTOLUS LIMITED
Reel/Frame 061319/0651 →
Priority Claims (1)
GB 1919019 · Dec 20, 2019 · national
Continuity (1)
Related Publication 20240252534A1 · Aug 1, 2024
References Cited (33)
US 20190144561A1 · McGuinness et al. · 2019 [cited by applicant]
CN 108640999A · 2018 [cited by applicant]
CN 110526976A · 2019 [cited by applicant]
CN 110526984A · 2019 [cited by applicant]
JP 2019523651A · 2019 [cited by applicant]
WO WO03080672A1 · 2003 [cited by applicant]
WO WO2013153391A1 · 2013 [cited by applicant]
WO WO2015150771A1 · 2015 [cited by applicant]
WO WO2016030691A1 · 2016 [cited by applicant]
WO WO2016111344A1 · 2016 [cited by applicant]
WO WO2016124930A1 · 2016 [cited by applicant]
WO WO2016135470A1 · 2016 [cited by applicant]
WO WO2019173324A1 · 2019 [cited by applicant]
WO WO2019173636A1 · 2019 [cited by applicant]
Kloss C.C., et al., “Dominant-Negative TGF-Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication,” Supplemental Information, Molecular Therapy, Jul. 2018, vol. 26, No. 7… [cited by applicant]
Bui et al., “Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications,” Immunogenetics 57:304-314 (2005). [cited by applicant]
Calis et al., “Properties of MHC Class I Presented Peptides that Enhance Immunogenicity,” PLoS Comput. Biol. 9:e1003266 (2013). [cited by applicant]
Donnelly et al., “Analysis of the aphthovirus 2A/2B polyprotein cleavage mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal skip,” J. Gen. Virol. 82:1027-1041 (2001). [cited by applicant]
Gao et al., “Monoclonal antibody humanness score and its applications,” BMC Biotechnol. 13:55, 12 pages (2013). [cited by applicant]
Hassani et al., “Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer,” J Cell Biochem. 120(6):10787-10795 (2019). [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/GB2020/053289 dated Mar. 22, 2021. [cited by applicant]
Karosiene et al., “NetMHCcons: a consensus method for the major histocompatibility complex class I predictions,” Immunogenetics 64:177-186 (2012). [cited by applicant]
Kloss et al., “Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication”, Molecular Therapy, 26(7):1855-1866 (2018). [cited by applicant]
Nielsen et al., “Reliable prediction of T-cell epitopes using neural networks with novel sequence representations,” Protein Sci. 12:1007-1017 (2003). [cited by applicant]
Paul et al., “HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity,” J. Immunol. 191:5831-5839 (2013). [cited by applicant]
Peters et al., “Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method,” BMC Bioinformatics 6:132, 9 pages (2005). [cited by applicant]
Santoro et al., “A chimeric antigen receptor against prostate-specific membrane antigen, a tumor vasculature target”, Journal for ImmunoTherapy of Cancer, 1 (Suppl 1)::p. 33 (2013). [cited by applicant]
Santoro et al., “T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression”, Cancer Immunol Res 3(1):68-84 (2015). [cited by applicant]
Sette et al., “The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes,” J. Immunol. Baltim. 153:5586-5592 (1994). [cited by applicant]
Zhang et al., “The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding,” Bioinformatics 25:1293-1299 (2009). [cited by applicant]
Zuccolotto et al., “PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models”, PLOS ONE, 9(10):e109427, 12 pages (2014). [cited by applicant]
Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity”, Immunology, Proceedings of the National Academy of Sciences, 79:1979-1983 (1982). [cited by applicant]
Tamura et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only”, The J… [cited by applicant]